For the first time, the FDA has given approval for a fecal transplant therapy that can treat a bacterial infection associated with up to 30,000 deaths each year.
The treatment fights Clostridium difficile, or C.difficile, which leads to infections that can cause life-threatening diarrhea and inflammation of the colon.Called Rebyota, the therapy uses samples of microbes obtained from donor poop. It is administered through the rectum and adds good gut bacteria, which is important to healthy digestion.infection,” said Peter Marks, MD, PhD, director of the FDA’s Center for Biologics Evaluation and Research.
The FDA says certain situations, such as using antibiotics, can change the balance of microorganisms in the gut, allowing C. difficile to grow and release poisons. This can lead to diarrhea, abdominal pain, fever, organ failure, and death. The risks for getting CDI include being over age 65 and having a weakened immune system. Patients can get it again even after it’s been successfully treated.
“The risk of additional recurrences increases with each infection and treatment options for recurrent CDI are limited,” the FDA said. “The administration of fecal microbiota is thought to facilitate restoration of the gut flora to prevent further episodes of CDI.” Swiss Ferring Pharmaceuticals became the owner of this therapy through its 2018 purchase of U.S.-based Rebiotix, Reuters reported.Reuters: “U.S. FDA gives first-ever approval to fecal transplant therapy.”
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Caméra de recul : Honda rappelle 115 000 Ridgeline | Actualités automobile | Auto123Honda procède au rappel de 115 000 Ridgeline en raison d’un problème potentiel avec la caméra de recul. Auto123 a les infos.
Read more »
Audi rappelle 50 000 véhicules pour une raison incroyable | Actualités automobile | Auto123Audi procède au rappel d’environ 50 000 véhicules pour une raison plutôt bizarre. Auto123 a les détails.
Read more »
U.S. FDA gives first-ever approval to fecal transplant therapyThe U.S. health regulator on Wednesday approved Switzerland-based Ferring Pharmaceuticals' fecal transplant-based therapy to reduce the recurrence of a bacterial infection, making it the first therapy of its kind to be cleared in the United States.
Read more »
FDA OKs First Fecal Transplant Therapy for Recurrent C difficileRebyota, a microbiota-based live biotherapeutic prepared from human stool, is intended for use after an individual has completed antibiotic treatment for recurrent C difficile infection.
Read more »
U.S. FDA gives first-ever approval to fecal transplant therapyThe therapy, Rebyota, targets Clostridium difficile, or C. difficile – a superbug responsible for infections that can cause serious and life-threatening diarrhea. In the United States, the infection is associated with 15,000-30,000 deaths annually. While this is the first such therapy approved by the Food and Drug Administration (FDA) for recurrent C. difficile infections, fecal microbiota transplants – classified by the regulator as investigational – have long been the standard of care in the U.S. for this condition.
Read more »
FDA clears 1st fecal transplant treatment for gut infectionWASHINGTON (AP) — U.S. officials have approved the first pharmaceutical-grade version of the so-called fecal transplant procedures that doctors have increasingly used against hard-to-treat intestinal infections.
Read more »